Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ACP3 | P15309 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742656 | 0.90 | KDM4E (0.37) | ALDH1A1KDM4EHPGDACP3KMT2A | |
| SCHEMBL472204 | 0.88 | ALDH1A1 (0.36) | ALDH1A1KDM4EHPGDL3MBTL1LMNA | |
| SCHEMBL874259 | 0.86 | ALDH1A1 (0.33) | ALDH1A1KDM4EHPGDACP3KMT2A | |
| SCHEMBL472186 | 0.84 | SIGMAR1 (0.35) | ALDH1A1KDM4EHPGDACP3KMT2A | |
| SCHEMBL873042 | 0.83 | KDM4E (0.35) | ALDH1A1KDM4EHPGDACP3L3MBTL1 | |
| SCHEMBL472178 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4EHPGDL3MBTL1LMNA | |
| SCHEMBL20162506 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4EHPGDL3MBTL1LMNA | |
| SCHEMBL12496458 | 0.83 | CTSG (0.39) | ALDH1A1KDM4EHPGDACP3KMT2A | |
| SCHEMBL472185 | 0.81 | SIGMAR1 (0.33) | ALDH1A1KDM4EHPGDACP3KMT2A | |
| SCHEMBL20162498 | 0.79 | POLB (0.42) | ALDH1A1KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3447061-B1 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHORAMIDATE DERIVATIVE OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20190201432-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | CARDIFF UNIVERSITY (GB) | 2019-07-04 | — | — | US | disclosed |
| EP-3031812-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-08-01 | — | — | EP | disclosed |
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3031812-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| EP-2681227-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana Biomed Limited (GB) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117246-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LIMITED (GB) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012103990-A1 | PHOSPHORAMIDATES OF MONOSACCHARIDES | BIOIBERICA, S.A. (ES) | 2012-08-09 | — | — | WO | disclosed |
| EP-2471802-A1 | Phosphoramidates of monosaccharides | Bioiberica, S.A. (ES) | 2012-07-04 | — | — | EP | disclosed |
| EP-2412717-A1 | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus | University College Cardiff Consultants, Ltd. (GB) | 2012-02-01 | — | — | EP | disclosed |
| EP-2097434-B1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS | UNIV CARDIFF (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-2097434-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS | University College Cardiff Consultants Ltd. (GB) | 2009-09-09 | — | — | EP | disclosed |
| EP-1928475-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-SUBSTITUTED PRONUCLEOTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008062206-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007020193-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | ALDH1A1 2409/4885KDM4E 3452/4885HPGD 1650/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | ALDH1A1 2369/4885KDM4E 3419/4885HPGD 1653/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | ALDH1A1 2381/4885KDM4E 3371/4885HPGD 1659/4885 |
| US-20190201432-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | ALDH1A1 2528/4885KDM4E 3292/4885HPGD 1819/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | ALDH1A1 2432/4885KDM4E 3294/4885HPGD 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.